Impact of serogroup A meningococcal conjugate vaccine for Africa.


Stuart, JM; (2017) Impact of serogroup A meningococcal conjugate vaccine for Africa. Human vaccines & immunotherapeutics. ISSN 2164-5515 DOI: https://doi.org/10.1080/21645515.2017.1412022

[img] Text - Accepted Version
Restricted to Repository staff only until 1 December 2018.
License:

Download (690kB) | Request a copy

Abstract

The introduction of a serogroup A meningococcal conjugate vaccine in the African meningitis belt has been a remarkable success. Meningitis due to the serogroup A meningococcus, previously responsible for most epidemics, has fallen by 99% in vaccinated countries. Success must, however, not distract from the continuing burden of meningitis in this region of Africa. The number of all meningitis epidemics at health district level has fallen by 60% following vaccination, but epidemics due to other meningococcal serogroups continue and may be increasing. The introduction of low cost multivalent conjugate vaccines must be given high public health priority.

Item Type: Article
Faculty and Department: Faculty of Infectious and Tropical Diseases > Dept of Disease Control
PubMed ID: 29194010
URI: http://researchonline.lshtm.ac.uk/id/eprint/4645537

Statistics


Download activity - last 12 months
Downloads since deposit
0Downloads
22Hits
Accesses by country - last 12 months
Accesses by referrer - last 12 months
Impact and interest
Additional statistics for this record are available via IRStats2

Actions (login required)

Edit Item Edit Item